Operator fluency on fresh ground

Curis, Inc. (CRIS) — this company's answers

The model's full reasoning — Q1 2016 call → NOWe need to answer YES or NO based on the transcript. The question asks: "When analysts probe a RECENTLY EMERGED positive element of the business — something whose meaningful contribution began only within roughly the last few quarters — does management respond with UNHESITATING, GRANULAR OPERATIONAL COMMAND: answering follow-up questions about that new element with specific, present-tense working detail ... while conveying that the element's contribution to the reported results is still early?" We need to identify if such a dynamic exists in the transcript. The analysts probe several things: CUDC-907 Phase 2, CA170, IRAK4 inhibitor, etc. The "recently emerged positive element" could be CA170, which is about to enter clinic (first orally administered checkpoint antagonist). Or CUDC-907's MYC alteration correlation. Or the Phase 2 trial. But we need to see if management answers with granular operational detail across at least two exchanges, and conveys that contribution is still early. Let's examine the Q&A. There are three analysts: Adnan Butt, Brian Skorney, Peter Lawson. Adnan Butt asks about CUDC-907: "have you discussed any response thresholds with the agency?" and "could something emerge from the combination data that could alter your plans for monotherapy?" Ali responds with general strategy, not granular operational detail. He talks about Phase 1 data, response rates, regulatory path. No specific working detail like how many sites, enrollment rates, etc. Then Adnan asks about CA170: "What's the rationale for expecting or actually enrolling patients who might of failed checkpoint inhibitors already in the Phase 1?" Ali explains mechanism of action, VISTA, etc. That's more about rationale, not operational detail. Then Adnan asks "But just to be clear, you do see value as an alternative to antibodies, right, even in naïve patients or patients new to therapy?" Ali says yes. Then Adnan asks "Any update on the IRAK4 inhibitor?" Ali says progressing, mentions AACR presentation. That's not granular.

← Back to the full CRIS analysis